Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Payables (2016 - 2025)

Fate Therapeutics' Payables history spans 14 years, with the latest figure at $2.7 million for Q4 2025.

  • For Q4 2025, Payables fell 71.64% year-over-year to $2.7 million; the TTM value through Dec 2025 reached $2.7 million, down 71.64%, while the annual FY2025 figure was $2.7 million, 71.64% down from the prior year.
  • Payables reached $2.7 million in Q4 2025 per FATE's latest filing, down from $3.5 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $11.4 million in Q1 2022 to a low of $2.7 million in Q4 2025.
  • Average Payables over 5 years is $6.9 million, with a median of $6.6 million recorded in 2021.
  • Peak YoY movement for Payables: soared 98.45% in 2024, then plummeted 71.64% in 2025.
  • A 5-year view of Payables shows it stood at $8.6 million in 2021, then dropped by 4.03% to $8.3 million in 2022, then crashed by 42.9% to $4.7 million in 2023, then surged by 98.45% to $9.4 million in 2024, then tumbled by 71.64% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Payables are $2.7 million (Q4 2025), $3.5 million (Q3 2025), and $4.0 million (Q2 2025).